Live Breaking News & Updates on Clinical oncology

Stay informed with the latest breaking news from Clinical oncology on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical oncology and stay connected to the pulse of your community

ASCO 2024 | Ascentage Pharma To Present Four Studies, Including An Oral Report Featuring The Latest Data Of Olverembatinib In SDH-Deficient GIST

ASCO 2024 | Ascentage Pharma To Present Four Studies, Including An Oral Report Featuring The Latest Data Of Olverembatinib In SDH-Deficient GIST
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Melbourne , Victoria , Australia , Rockville , Illinois , United-states , Chicago , Guangdong , Jilin , China , Mccormick-place , Guangzhou

Research reveals potential target for enfortumab vedotin therapy in urothelial carcinoma

Under the leadership of PD Dr. Niklas Klümper, Assistant Physician at the Department of Urology at the University Hospital Bonn (UKB) and Clinician Scientist of the BMBF-funded ACCENT program and PD Dr. Markus Eckstein, senior physician at the Institute of Pathology at the Uniklinikum Erlangen of the Friedrich-Alexander-University Erlangen-Nürnberg (FAU), an interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the antibody-drug conjugate enfortumab vedotin.

Bonn , Nordrhein-westfalen , Germany , Markus-eckstein-uniklinikum-erlangen , Uniklinikum-erlangen , Markus-eckstein , Department-of-urology , University-hospital-bonn , Institute-of-pathology , Hospital-bonn , Assistant-physician , Clinician-scientist

Can aspirin help prevent cancer? What do studies say

Aspirin may be useful in the treatment and prevention of colorectal cancer, according to recent research that was published in the journal "Cancer." T

India , United-states , Andrew-chan , Roberts-bresalier , Us-preventive-services-task-force , Harvard-medical-school , Services-task-force , Nature-reviews-cancer- , Clinical-oncology ,

Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Chicago , Illinois , United-states , France , Paris , France-general- , American , Guillaume-bayre , Ashleyr-robinson , Weid-europe , American-society-of-clinical-oncology , Head-of-external-communications

Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

FOR IMMEDIATE RELEASE:

Compugen to Present New Clinical Data Showing COM701 Triple

Combination Preliminary Anti-Tumor Activity in

...

Israel , Chicago , Illinois , United-states , Tel-aviv , San-francisco , California , American , Manish-sharma , Yvonne-naughton , Tel-aviv-stock-exchange , Corporate-communications

HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab

HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Joern-aldag , Michael-kaiser , Hookipa-pharma-inc , Nasdaq , American-society-of-clinical-oncology , Pharma-inc , Drug-administration , University-of-chicago-medicine , Exchange-commission , European-society-for-medical-oncology-annual-congress

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Austria , Vienna , Wien , United-states , American , Joern-aldag , Michael-kaiser , American-society-of-clinical-oncology , European-society-for-medical-oncology-annual-congress , Drug-administration , Exchange-commission , University-of-chicago-medicine

Lucio N. Gordan, MD Discusses Findings of Phase 3 Clinical Trial Supporting Advanced Treatments for Multiple Myeloma in National Broadcast

/PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio Gordan, MD will join a panel of industry...

United-states , Florida , American , America , Lucio-gordan , Florida-cancer-specialists-research-institute , Prnewswire-florida-cancer-specialists-research-institute , American-society-of-clinical-oncology , Cancer-specialists , Research-institute , Managing-physician-lucio-gordan , Indirect-treatment-comparison

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...

Austria , Vienna , Wien , United-states , American , Joern-aldag , Michael-kaiser , European-society-for-medical-oncology-annual-congress , Company-type , Pharma-inc , Drug-administration , American-society-of-clinical-oncology

Theriva Biologics, Inc.: Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics, Inc.: Theriva Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , Chicago , Illinois , Rockville , American , Dennis-riedl , Theriva-biologics , Chris-calabrese , American-society-of-clinical-oncology , Lifesci-advisors , Theriva-biologics-inc , Clinical-oncology